Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Bayer wins Arkansas trial over Roundup cancer claims

Published 01/03/2024, 22:42
Updated 02/03/2024, 00:17
© Reuters. FILE PHOTO: Bottles of Roundup, a brand owned by Bayer, are seen for sale in a store in Manhattan, New York City, U.S., June 30, 2022. REUTERS/Andrew Kelly/File Photo

By Brendan Pierson

(Reuters) -Bayer on Friday evening won a trial in a lawsuit brought by the family of an Arkansas woman who says she developed cancer from exposure to Roundup, one of thousands of lawsuits the German company is facing over the weedkiller, while another trial ended with a hung jury earlier in the day.

A jury in the Circuit Court of Conway County found that Bayer (ETR:BAYGN) was not responsible for the cancer that killed Wanda Cody, who used Roundup at her place of business, the company said.

Lawyers for Cody's family, who sued Bayer, could not immediately be reached for comment.

The verdict came hours after Delaware Superior Court Judge Vivian Medinilla declared a mistrial in a separate case brought by the family of deceased South Carolina groundskeeper Anthony Cloud. Jurors in that case had said they could not agree on a verdict after more than three days of deliberations.

A lawyer for the Cloud family could not immediately be reached for comment. The family can still pursue another trial.

Around 165,000 claims have been made in the U.S. against Bayer for personal injuries allegedly caused by Roundup, which the company acquired as part of its $63 billion purchase of U.S. agrochemical company Monsanto (NYSE:MON) in 2018.

Most plaintiffs, including Cloud's and Cody's families, allege that the product caused a type of cancer called non-Hodgkins lymphoma.

Bayer has said that decades of studies have shown Roundup and its active ingredient, glyphosate, are safe for human use.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Roundup is among the most widely used weedkillers in the United States, though Bayer phased out its sales for home use last year.

Bayer has now won 11 of the last 18 Roundup trials, but plaintiffs have scored large verdicts totaling more than $4 billion, including $2.25 billion in a single case in January.

The company is appealing those verdicts, which include large punitive damages awards that are likely to be reduced because they exceed U.S. Supreme Court guidance.

The losses have led some investors to question Bayer's legal strategy in defending the Roundup cases, though the company has so far held firm that it will fight them in court.

In 2020, Bayer settled most of the then-pending Roundup cases for up to $9.6 billion but failed to get a settlement covering future cases. More than 50,000 claims remain pending, and at least 10 additional Roundup trials are expected later this year.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.